Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

European journal of haematology·2026

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Hematological oncology·2024

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

European journal of haematology·2024

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.

Annals of hematology·2024

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

Frontiers in pharmacology·2023

EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.

Virchows Archiv : an international journal of pathology·2022

Reduced erythrocyte deformability in some hematological diseases: how this can affect the primary hyperviscosity syndromes (PHS) classification.

Acta haematologica·2026

The validation of simplified comorbidity index for predicting non-relapse mortality after allogeneic haematopoietic cell transplantation.

Acta haematologica·2026

Lactoferrin as a Natural Modulator of Immunity and Iron Homeostasis: A Review of Current Knowledge.

Acta haematologica·2026

Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia.

Acta haematologica·2026

Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.

Acta haematologica·2026

Navigating the Immune Landscape: Balancing Efficacy and Toxicity of B-Cell Maturation Antigen-Targeting Agents in Multiple Myeloma.

Acta haematologica·2026

Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study.

Frontiers in pharmacology·2026

Can we better evaluate responses in higher-risk myelodysplastic syndromes?

Haematologica·2026

Dynamics and clinical significance of coagulation abnormalities following CAR T-cell therapy.

Haematologica·2026

NEDD4 Promotes Hepatocellular Carcinoma Progression Through Ubiquitin-Dependent Degradation of EPHB6.

Cancer science·2026

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Leukemia & lymphoma·2026

WNT5A-Associated Osteogenic Enhancement Contributes to the Protective Effects of OPG-Fc in Glucocorticoid-Associated Femoral Head Osteonecrosis.

Biomolecules & therapeutics·2026

Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy

Related Experiment Videos

Related Concept Videos

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.

Reduced erythrocyte deformability in some hematological diseases: how this can affect the primary hyperviscosity syndromes (PHS) classification.

The validation of simplified comorbidity index for predicting non-relapse mortality after allogeneic haematopoietic cell transplantation.

Lactoferrin as a Natural Modulator of Immunity and Iron Homeostasis: A Review of Current Knowledge.

Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia.

Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.

Navigating the Immune Landscape: Balancing Efficacy and Toxicity of B-Cell Maturation Antigen-Targeting Agents in Multiple Myeloma.

Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study.

Can we better evaluate responses in higher-risk myelodysplastic syndromes?

Dynamics and clinical significance of coagulation abnormalities following CAR T-cell therapy.

NEDD4 Promotes Hepatocellular Carcinoma Progression Through Ubiquitin-Dependent Degradation of EPHB6.

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

WNT5A-Associated Osteogenic Enhancement Contributes to the Protective Effects of OPG-Fc in Glucocorticoid-Associated Femoral Head Osteonecrosis.

Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy

Related Experiment Videos

Related Concept Videos

Related Articles